Navigation Links
Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Date:7/26/2013

f the company's Executive Committee, Mr. Santini led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects, and the expansion of Lilly Ventures in the U.S. and China. In addition to Intarcia, Mr. Santini serves on the Boards of Directors of several other biopharmaceutical companies and an Italian financial holding company. Fluent in four languages, Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna, and an MBA from the Simon School of Business, University of Rochester.

Mr. Santini explained that his enthusiasm for joining the Intarcia Board is prompted most by the Company's potential opportunity to make a real difference in the lives of patients with type 2 diabetes:  "This is truly an exciting time in the evolution of Intarcia, and quite possibly in the future management of type 2 diabetes. I believe Intarcia has thoughtfully put together the handful of critical ingredients for major success: a differentiated and potentially game-changing lead product candidate, world-class scientific, manufacturing and business competencies, a strong Board and top-tier investors, and a proven team full of passion to outperform the marketplace and help patients. I look forward to working with the Board and senior leadership to help guide the company to the full measure of success possible."

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump (minipump) that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for exte
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Md. , Sept. 30, 2014  Tasly ... way to modernize medicine, announced today the launch ... of nutraceuticals developed to address men and women ... healthy and vibrant into old age while helping ... includes three condition-specific, whole-food and herb-based formulas, namely, ...
(Date:9/30/2014)... 30, 2014 Aileron Therapeutics, Inc. - ... Global Markets Direct,s, ,Aileron Therapeutics, Inc. - Product ... the Aileron Therapeutics, Inc.,s pharmaceutical research and development ... the current therapeutic developmental pipeline of Aileron Therapeutics, ... therapeutics assessment by drug target, mechanism of action ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... March 15, 2012  Continuing to meet the complex ... a US-based, ISO13485-certified, FDA compliant contract manufacturing and ... with FDA compliant storage and order fulfillment services ... Telcare,s FDA and HIPAA-compliant solution, ...
... 15, 2012 /PRNewswire-Asia-FirstCall/ --  Dehaier Medical Systems Ltd. ... emerging leader in the development, assembly, marketing and ... today announced that the Company plans to release ... full year of 2011 ended December 31, 2011 on Monday, March ...
Cached Medicine Technology:Cogmedix Provides Medical Device Storage and Order Fulfillment Services for Telcare Medical Supply 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... 01, 2014 First Warning Systems, a ... cellular changes throughout the body, announced the company is ... address the company’s breadth of upcoming product releases. The ... screening technology. , “Our initial focus will be an ... detects abnormal circadian cellular changes over time,” said Rob ...
(Date:10/1/2014)... from Duke Medicine suggests that some people who are ... hard-wired to gain weight when exposed to chronic stress, ... 13 percent of people, all of whom are Caucasian, ... help them reduce heart disease with simple interventions such ... "Genetic susceptibility, psychosocial stress and metabolic factors act in ...
(Date:10/1/2014)... Inc., announced today their new NoteSwift™ 2.0 for Allscripts ... the bridge between the EHR and Dragon Medical interpreting ... at the point of care. NoteSwift reduces the time ... than half – and virtually eliminates mouse clicks – ... EHR use according to the June 12, 2014 HIMSS ...
(Date:10/1/2014)... Watsonville, California (PRWEB) October 01, 2014 ... initiative to benefit a very special cause. The ... and support for Paws for Veterans, a nonprofit ... veterans, while also rescuing shelter dogs that would ... purchases of featured products will support monthly donations ...
Breaking Medicine News(10 mins):Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... Residents forced to,leave their homes and businesses due to flooding ... their belongings. The Restoration Industry,Association (RIA, formerly ASCR) suggests that ... during an evacuation:, -- Health & homeowners ... irreplaceable mementos, disposable camera, digital ...
... /PRNewswire/ - Media representatives are invited,to a photo opportunity ... Schwarzenegger, the California Governor, in light of an,international collaboration ... BIO 2008 International Convention in San Diego., ... Health ...
... 18, 2008) -- Could injecting a gene into a ... life-threatening condition? Physician-scientists are setting out to answer that ... to treat severe heart failure. , NewYork-Presbyterian Hospital/Columbia ... New York City area where the therapy is currently ...
... More Components to Fully Measure Quality, WASHINGTON, ... today commended the Centers for Medicare & Medicaid,Services ... care through,the newly introduced "five-star" rating system, but ... index, any system that relies heavily,on survey data ...
... Diagnostic Technologies in Development for Use in ... ... & Johnson Nordic,AB, a Johnson & Johnson company, today announced ... vitro diagnostic (IVD) technologies,for use in Point-of-Care (POC) and near-patient ...
... Thousands of Racers and Sponsorship of Survivor Cafe Continues Longstanding ... Community Support By Binson,s, DETROIT, ... the May 31st Susan G. Komen Detroit Race for,the Cure(R) with the ... team., For 26 years, the Komen Race for the Cure Series ...
Cached Medicine News:Health News:Restoration Industry Association Provides Evacuation Checklist for Residents Impacted by Flooding 2Health News:First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia 2Health News:AHCA Emphasizes Quality Improvement in America's Nursing Homes 2Health News:Johnson & Johnson Nordic AB Acquires Amic 2Health News:Johnson & Johnson Nordic AB Acquires Amic 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 2Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 3Health News:Fight Against Breast Cancer Receives Big Boost During Susan G. Komen Detroit Race for the Cure(R) With 344 Participants From Binson's, Northwood 4
... is a widely used screening test for ... precision oriented Dispette branded system is considered ... tube stamp. No other system meets defined ... patient care. Specialized systems are also available ...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading....
... contains 266 amino acids and is variably N-glycosylated. ... estimates of between 43 and 56 kDa. Insulin-like ... with high affinity but do not bind insulin. ... characterized at this time, IGFBP-3 has been shown ...
... the detection and semi-quantitation ... Scl-70 antigen in serum ... the diagnosis of autoimmune ... be performed either manually ...
Medicine Products: